title: mTORC 2:1 for chemotherapy sensitization in glioblastoma.
abstract: mTOR signaling is frequently deregulated in cancer, including brain tumors. Although the signaling of mTOR complex 1 (mTORC1) has been subject to intensive investigations and mTORC1 itself has been a well-established cancer drug target for years, the role of the second complex, mTORC2, remains elusive. Tanaka et al. reveal an EGFRvIII-mTORC2-NFκB signaling cascade and demonstrate that mTORC2 mediates cisplatin resistance through NF-κB in an Akt-independent manner in glioblastoma. Uncovering the role of mTORC2 in chemotherapy resistance in glioblastoma highlights the need for further investigations of mTORC2 inhibition.
authors.affiliation: Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Department of Neurooncology at the National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany. wolfgang.wick@med.uni-heidelberg.de
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Wick
authors.forename: Jonas
authors.initials: J
authors.lastname: Blaes
authors.forename: Markus
authors.initials: M
authors.lastname: Weiler
mesh_terms: D001932:Brain Neoplasms / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism*; D005909:Glioblastoma / Q000378:metabolism*; D006801:Humans; D016328:NF-kappa B / Q000378:metabolism*; D014157:Transcription Factors / Q000378:metabolism*
chemical_list: C493245:CRTC2 protein, human; D016328:NF-kappa B; D014157:Transcription Factors; C410723:epidermal growth factor receptor VIII; D066246:ErbB Receptors